In the last trading session, 1.38 million shares of the Moleculin Biotech Inc (NASDAQ:MBRX) were traded, and its beta was 1.94. Most recently the company’s share price was $1.15, and it changed around -$0.14 or -10.85% from the last close, which brings the market valuation of the company to $13.81M. MBRX currently trades at a discount to its 52-week high of $10.35, offering almost -800.0% off that amount. The share price’s 52-week low was $0.40, which indicates that the current value has risen by an impressive 65.22% since then.

Moleculin Biotech Inc stock received a consensus recommendation rating of Hold, based on a mean score of 1.67. If we narrow it down even further, the data shows that 0 out of 2 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 1 recommended MBRX as a Hold, whereas 0 deemed it a Buy, and 0 rated it as Underweight. Moleculin Biotech Inc is expected to report earnings per share of 0 for the current quarter.

Moleculin Biotech Inc (NASDAQ:MBRX) trade information

Instantly MBRX has showed a red trend with a performance of -10.85% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 1.6400 on recent trading dayincreased the stock’s daily price by 29.88%. The company’s shares are currently down -32.35% year-to-date, but still up 7.48% over the last five days. On the other hand, Moleculin Biotech Inc (NASDAQ:MBRX) is -25.32% down in the 30-day period.

Forecasts for the next quarter put sales growth at 0.00%.

Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 18.25%. Moleculin Biotech Inc earnings are expected to increase by 49.55% in 2025, but the outlook is positive 36.38% per year for the next five years.

MBRX Dividends

Moleculin Biotech Inc’s next quarterly earnings report is expected to be released in April.